Biogen (BIIB) Stock Upgrade: Target Raised to $225 from UBS
Published on 4/22/2026
AI Summary
Summarized by AI from the source belowUBS has upgraded Biogen (BIIB) stock, citing favorable pipeline catalysts as a key reason. The target price for Biogen shares has been raised to $225. This adjustment reflects confidence in the company's growth potential and anticipated drug approvals. The upgrade may positively influence market perception and investor interest in Biogen moving forward.
Get the free market brief
Top stories and analysis, summarized. No spam, unsubscribe anytime.
